To Assess the Pharmacokinetics and Safety and Tolerability of Efanesoctocog Alfa (BIVV001)in Adults With Type 2N and 3 Von Willebrand Disease (VWD)

NCT04770935 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Von Willebrand's Disease (VWD)

Interventions

DRUG: efanesoctocog alfa (BIVV001)

Sponsor

Bioverativ, a Sanofi company